Skip NavigationSkip to Content
Return Return to Search Results

State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach

  1. Author:
    Levy, Elliot B
    Fiel, Maria I
    Hamilton, Stanley R
    Kleiner, David E
    McCall, Shannon J
    Schirmacher, Peter
    Travis, William
    Kuo, Michael D
    Suh, Robert D
    Tam, Alda L
    Islam, Shaheen U
    Ferry-Galow,Katherine
    Enos, Rebecca A
    Doroshow, James H
    Makhlouf, Hala R

  2. Author Address

    Center for Interventional Oncology, Radiology and Imaging Sciences and Center for Cancer Research, National Institutes of Health, Bethesda, MD., Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY., Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Laboratory of Pathology, National Institutes of Health, Bethesda, MD., Department of Pathology, Duke University, Durham, NC., Institute of Pathology, University of Heidelberg, Heidelberg, Germany., Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY., Department of Radiology Medical Artificial Intelligence Laboratory Initiative, The University of Hong Kong, Hong Kong., Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, CA., Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX., Division of Pulmonary, Critical Care & Sleep Medicine, Medical College of Georgia, Augusta University, Augusta, GA., Laboratory of Human Toxicology and Pharmacology, Applied/ Developmental Research Support Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, MD., The EMMES Corporation, Rockville, MD., Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.,
    1. Year: 2020
    2. Date: MAY 10
    3. Epub Date: 2020 03 05
  2. Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    1. 38
    2. 14
    3. Pages: 1633-+
  4. Type of Article: Article
  5. Article Number: JCO1902322
  6. ISSN: 0732-183X
  1. Abstract:

    PURPOSE National Cancer Institute (NCI)-sponsored clinical trial network studies frequently require biopsy specimens for pharmacodynamic and molecular biomarker analyses, including paired pre- and post-treatment samples. The purpose of this meeting of NCI-sponsored investigators was to identify local institutional standard procedures found to ensure quantitative and qualitative specimen adequacy. METHODS NCI convened a conference on best biopsy practices, focusing on the clinical research community. Topics discussed were (1) criteria for specimen adequacy in the personalized medicine era, (2) team-based approaches to ensure specimen adequacy and quality control, and (3) risk considerations relevant to academic and community practitioners and their patients. RESULTS AND RECOMMENDATIONS Key recommendations from the convened consensus panel included (1) establishment of infrastructure for multidisciplinary biopsy teams with a formalized information capture process, (2) maintenance of standard operating procedures with regular team review, (3) optimization of tissue collection and yield methodology, (4) incorporation of needle aspiration and other newer techniques, and (5) commitment of stakeholders to use of guideline documents to increase awareness of best biopsy practices, with the goal of universally improving tumor biopsy practices.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1200/JCO.19.02322
  3. PMID: 32134701
  4. View record in Web of Science®
  5. WOS: 000537768800013

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel